Company Announcement no. 37/2008
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, December 22, 2008
LifeCycle Pharma Announces Financial Calendar for 2009
LifeCycle Pharma A/S (OMX:LCP) announces the financial calendar for 2009:
March 3, 2009: Release of Annual Report 2008.
April 23, 2009: Annual General Meeting
May 14, 2009: Interim Report for 1st Quarter - results from January 1 to
March 31, 2009.
August 19, 2009: Interim Report for the 2nd Quarter - results from January 1
to June 30, 2009.
November 11, 2009: Interim Report for the 3rd Quarter - results from January 1
to September 30, 2009.
For more information, please contact:
LifeCycle Pharma A/S
Dr. Jim New Peter Schøtt Knudsen
President & Chief Executive Officer Head of Investor Relations
Phone: +45 7033 3300 Phone: +45 7033 3300
Email: JSN@lcpharma.com E-mail: PSK@lcpharma.com
About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and to combat certain
cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a cholesterol-lowering
product, FenoglideTM, currently on the U.S. market and a diversified near- and
medium-term pipeline with five product candidates in clinical trials and one in
preclinical development. LCP is listed on the OMX Nordic Exchange Copenhagen
under the trading symbol (OMX: LCP). For further information, please visit
www.lcpharma.com.
